so by swapping out the ad5 for the astrazeneca adenovirus vaccine, the astrazeneca—oxford vaccine, that would actually make a lot of sense in terms of producing a safer and possibly more what we call immunogenic vaccine — that's point one. and from a regulatory point of view, the russians have had a number of issues in terms of quality and quality assurance and meeting standards that one would ordinarily expect for the uk and the us, and so by partnering now with astrazeneca—oxford, i think it will lift — lift their boat a lot and make a better vaccine for not only for russia, but they're aggressively trying to export it and make a better vaccine for the world. you talk about lifting the boat for them but of course, the oxford—astrazenica vaccine has, in the us, has come in for criticism about the way it is communicated, about some of the way the data of its trials have been released. do you share any of those concerns? you know, ultimately, i think, it's — well, first of all, we need this vaccine to work and the us cannot vaccinate our population just with the two mrna vaccin

oxford in the new year,j j and astrazeneca oxford in the new year, j andj may be february and same as astrazeneca oxford in the spring so as we move into the summer, we will certainly head towards that but the good news is that hopefully with each passing month now, will gradually start to see more and more americans get vaccinated and you know unfortunately we never launched a national covid containment programme to be kind of backed ourselves into a corner where we have become com pletely corner where we have become completely dependent on a biotechnology for the solution. we will have to vaccinate our way out of this. i was hoping we we re way out of this. i was hoping we were not going to be so com pletely we were not going to be so completely dependent on it but that was the way things rolled out with the white house not leading a national programme and so as we move towards vaccinating the us population, the other piece to this is we're going to need adolescent, may be kids vaccinated and we're going to have to maximise our communication strategy, which we really not had yet. ho

oxford—astrazeneca vaccine manufactured ? the oxford—astrazeneca vaccine manufactured? the concern is the supply chain could take longer to reach some parts of the world. that's something that is not controlled by the university of oxford but is determined by astrazeneca. one of the reasons the university partnered with astrazeneca is because it has an extensive network of manufacturing capabilities and supply and logistics around the world, which means that it's going to be very rapidly upscaling production and delivering the vaccine across the world. for the uk vaccine, and this will be manufactured both in the uk and the netherlands, the real advantage of the oxford vaccine is it can be stored between two and 8 degrees, so in a normalfridge, and thatis degrees, so in a normalfridge, and that is how most vaccines are normally rolled out across the country and the world. childhood immunisations or travel vaccines are usually stored at that temperature. we can tap into the existing logistics networks used by health ca re logistics networks used by health care profession

so by swapping out the ad5 for the astrazeneca adenovirus vaccine, the astrazeneca—oxford vaccine, that would actually make a lot of sense in terms of producing a safer and possibly more what we call immunogenic vaccine — that's point one. and from a regulatory point of view, the russians have had a number of issues in terms of quality and quality assurance and meeting standards that one would ordinarily expect for the uk and the us, and so by partnering now with astrazeneca—oxford, i think it will lift — lift their boat a lot and make a better vaccine for not only for russia, but they're aggressively trying to export it and make a better vaccine for the world. you talk about lifting the boat for them but of course, the 0xford—astrazenica vaccine has, in the us, has come in for criticism about the way it is communicated, about some of the way the data of its trials have been released. do you share any of those concerns? you know, ultimately, i think, it's — well, first of all, we need this vaccine to work and the us cannot vaccinate our population just with the two mrna vaccin

, j&j maybe february and same as astrazeneca oxford in the spring, so as we move into the summer, we'll certainly head towards that, but the good news is that hopefully with each passing month now, we'll gradually start to see more and more americans get vaccinated and, you know, unfortunately we never launched a national covid containment programme so we kind of backed ourselves into a corner where we have become completely dependent on a biotechnology for the solution. we will have to vaccinate our way out of this. i was hoping we were not going to be so completely dependent on it, but that was the way things rolled out with the white house not leading a national programme and so, as we move towards vaccinating the us population, the other piece to this is we're going to need adolescents, maybe kids vaccinated, and we're going to have to maximise our communication strategy, which we really haven't had yet. how strong do you think any resistance will be to this vaccination programme? so the kaiser family foundation just released a survey this week and it identified two groups that so f

, j&j maybe february, same as astrazeneca oxford in the spring, so as we move into the summer, we'll certainly head towards that, but the good news is that hopefully with each passing month now, we'll gradually start to see more and more americans get vaccinated and, you know, unfortunately we never launched a national covid containment programme so we kind of backed ourselves into a corner where we have become completely dependent on a biotechnology for the solution. we're going to have to vaccinate our way out of this. i was hoping we were not going to be so completely dependent on it, but that was the way things rolled out with the white house not leading a national programme and so, as we move towards vaccinating the us population, the other piece to this is we're going to need adolescents, maybe kids vaccinated, and we're going to have to maximise our communication strategy, which we really haven't had yet. how strong do you think any resistance will be to this vaccination programme? so the kaiser family foundation just released a survey this week and it identified two groups th

, j&j maybe february and same as astrazeneca oxford in the spring, so as we move into the summer, we'll certainly head towards that, but the good news is that hopefully with each passing month now, we'll gradually start to see more and more americans get vaccinated and, you know, unfortunately we never launched a national covid containment programme so we kind of backed ourselves into a corner where we have become completely dependent on a biotechnology for the solution. we will have to vaccinate our way out of this. i was hoping we were not going to be so completely dependent on it, but that was the way things rolled out with the white house not leading a national programme and so, as we move towards vaccinating the us population, the other piece to this is we're going to need adolescents, maybe kids vaccinated, and we're going to have to maximise our communication strategy, which we really not had yet. how strong do you think any resistance will be to this vaccination programme? so the kaiser family foundation just released a survey this week and it identified two groups that so far a

of the astrazeneca oxford vaccine. accelerate its vaccination program, how big an economic impact do you think that will have? how big an advantage? >> we are in a race against a mutant strain of covid, and the impact that is having on the southeast of england is immense. the economic impact that is going to have could also big pretty big -- could also be pretty big, too. it may not help for the first couple of months enough to really avoid the economic impact of this extended lockdown that i think we are going to see. maybe we get to the spring and we get enough people vaccinated to start coming out of this kind of broad lockdown, we start moving down through the tears, maybe late february, march, and maybe back into a normal situation in april. everything we have seen from this vaccine from march last year has told us that it takes much longer than you would expect. that there will be surprises along the way that will largely not be pleasant, and i think that's what we have to prepare ourselves for. i'm afraid that r

approves the oxford astrazeneca coronavirus vaccine. the country's health secretary predicts a path out of the pandemic by spring. >>> sounding the alarm. the u.s. president-elect joe biden says the president's vaccine plans are falling short. >>> and an historic vote. scenes of celebration and disappointment as argentina moves to legalize abortion. hello and a very warm welcome to our viewers in the united states and around the world. i'm isa ar

they have licensing agreements with the oxford astrazeneca vaccine, for example. we have seen manufacturing become available in ramped up places like brazil, thailand, south africa. we think that is important to make sure when a vaccine is context,red in l imt low and middle income countries, becomes much more likely that local and regional populations will get access to those. that is one trend. without telling particularly with the i.t. challenge perhaps, but a mechanism -- manufacturing capacity that we are starting to see an uptick in availability over time. , youen: dr. udayakumar mentioned the astrazeneca oxford vaccine, which is more suitable for developing countries because it is easier to transport and also the serum institute will be manufacturing it. do you expect the astrazeneca oxford vaccine to be more readily available in the developing countries also because they have committed a certain percentage of their vaccines to developing countries -- which i don't believe either moderna or moderna have, though perhaps at this point they have? >> you are ex

unlike pfizer's, which needs ultra low temperatures, the oxford astrazeneca vaccine can be transported in a fridge, meaning every care home in the uk should now be in reach. the medicines regulator said no corners had been cut. with this approval of the second vaccine, we are another step closer in helping to defeat this virus. 0ur clear message is that you can have every confidence in the safety, in the effectiveness and in the quality of covid—19 vaccine astrazeneca. the vaccine uses a gene from the spike shaped protein on the surface of coronavirus. this is put inside a modified harmless virus. the vaccine instructs human cells to make the spike protein, which prompts the immune system to create antibodies, which can recognise and destroy coronavirus. and it stimulates t—cells, which should destroy cells that have become infected. so just how effective is the vaccine? the latest estimate is it gives 70% protection against covid three weeks after the first dose. the nhs will now hold back giving the second dose of all covid vaccines until 12 weeks so more people can get protected

approves the oxford astrazeneca coronavirus vaccine. the country's health secretary predicts a path out of the pandemic by spring. >>> sounding the alarm. the u.s. president-elect joe biden says the president's vaccine plans are falling short. >>> and an historic vote. scenes of celebration and disappointment as argentina moves to legalize abortion. hello and a very warm welcome to our viewers in the united states and around the world. i'm isa suarez. "cnn newsroom" starts right now. >>> this is cnn breaking news. >>> it is 9 a.m. here in london and we start this hour with breaking news out of the u.k. where the government says regulators have approved the oxford astrazeneca coronavirus vaccine. it becomes the second vaccine authorized for use here in the u.k. the british prime minister is celebrating the approval. it is truly fantastic news and a triumph for british science that the oxford astrazeneca vaccine has been approved for use. we will work to vaccinate as many people as possible. cnn's phil black joins me here in london with t

the medicines regulator gave the go—ahead for the oxford astrazeneca vaccine. it isa the oxford astrazeneca vaccine. it is a landmark moment in the fight against coronavirus. other million doses have been available —— made available next week. daw .5 years after britain voted in a referendum to leave european union by gems parliament in london have approved a new free trade deal finalised last week stop prime minister borisjohnson said britain is marking a new beginning in its relationship with the eu. ten people have been injured, one critically, in a landslide that buried houses in aim norwegian municipality north—east of oslo. 11 people are not accounted for. it's not clear if someone caught up in the landslide or simply away when it happened. -- if —— if somewhat well.

today the uk medicines regulator gave the go—ahead for the oxford astrazeneca vaccine — signalling a landmark moment in the fight against coronavirus. it comes as the uk announced a further 981 deaths in the past 2a hours — the highest figure since april. here is our medical editor, fergus walsh. the approval of the oxford vaccine, which is a fantastic achievement for british science... it's a great day, we are very proud. this is a really significant moment in the fight against this pandemic. it is, i think, again, a changing moment. this is the vaccine — more than any other — that will eventually bring coronavirus under control. unlike pfizer's, which needs ultra low temperatures, the oxford astrazeneca vaccine can be transported in a fridge, meaning every care home in the uk should now be in reach. the medicines regulator said no corners had been cut. with this approval of the second vaccine, we are another step closer in helping to defeat this virus. our clear message is that you can have every confidence in the safety, in the effectiveness and in the quality of covid—19

the oxford astrazeneca one would speed it up enormously. you still run into how many people are available to give the vaccinations. there is no question it would add speed. i think people are almost taking .hat for volatile anxious on the help already. guy: let's talk about a couple of issues to come up in the next couple of days. what is the tolerance of the british population for a tier five? it was talked about yesterday in the media as a possibility because the new variance is causing the old numbers to spike and we have the post christmas spike to deal with as well. in such a scenario, do you think gove,johnson, michael gavin williamson would be able to shut secondary stores possibly for a month? what do you think the tolerance is for that? public: i think the tolerance for tighter restrictions or continuing , people arerictions exhausted, they are afraid. the stories of the strains on livelihoods, mental health, all of that is growing. i think people would absolutely get behind it. the secondary schools is a really difficult one. it a

the approval of the oxford astrazeneca vaccine, which is a fantastic achievement for british science. it's a great day, we're very proud. this is a really significant moment in the fight against this pandemic. it is, i think, a game—changing moment. this is the vaccine, more than any other, that will eventually bring coronavirus under control. unlike pfizer's, which needs ultralow temperatures, the oxford astrazeneca vaccine can be transported in a fridge, meaning every care home in the uk should now be in reach. the medicines regulator said no corners had been cut. with this approval of the second vaccine, we are another step closer in helping to defeat this virus. 0ur clear message is that you can have every confidence in the safety, in the effectiveness and in the quality of covid—19 vaccine astrazeneca. the vaccine uses a gene from the spike—shaped protein on the surface of coronavirus. this is put inside a modified, harmless virus. the vaccine instructs human cells to make the spike protein, which prompts the immune system to create antibodies which can recognise and destro

the data packages for the astrazeneca—oxford vaccine have been arriving. we do expect a further package in the coming days. the committees would be aware of the publication in the lancetjust yesterday, a peer—reviewed journal testifying to the excellent and intensive work that has been done by the oxford group and astrazeneca. i would not be able to give the committees a firm date because the review is clearly a very active review. there will be questions and deliberations that we will be pursuing in exactly the same way as we have done for pfizer—biontech. then the committees quizzed some familiar witnesses — did the arrival of the vaccine mean that restrictions could be relaxed because the risks were now lower? we're not there yet. for the next three months... i want to be very clear, for the next three months, we will not have sufficient protection. we're going through the most difficult time of year for respiratory infections and the most difficult time of year for the nhs, so the idea we can suddenly stop now because the vaccine‘s here, that w

they are planning to try a combination of the oxford astrazeneca and nie russian spk v vaccine. although it is not clear how may people wl be involved. our correspondent has more on that. >> this is an intriguing bit of news even the language we have heard previously, specifically from the russian backers of the sputnik v vaccine. it has not exactly been a warm relationship of words, so this is an interestingorotential collion. what we heard from astrazeneca came in the form of a press will start recruiting volunteers in trials to see whether using the oxford astrazeneca vaccine with a second jab of the sputnik vaccine could boost immunity and create better protection against coronavirus and essentially resolve problems with accessibility to vaccines around the world generally. if you can mix andvaatch differenines, that it -- that potentially helps with production flows and problems, supplying vaccines to different parts of t world. it's an interesting potential collaboration. the details are pretty scarce. the company backing the russian vaccine ggests the trials could start a

astrazeneca oxford university shots gained approval yesterday. the capacity to effectively deliver the vaccines from pfizer and astrazeneca. zeneca canof after potentially manufacture to million doses a week. we have the infrastructure to deploy that. at the moment my limitation is the speed at which we can get deliveries from both astrazeneca and pfizer, not the infrastructure. joining us now is bloomberg's emma chandra, who spoke with the minister. more restrictions for more of england. what exactly is the scope? toa: 20 million people added the tier four restrictions, meaning 78% of the english population is facing the toughest restrictions in the u.k., and those tough restrictions -- tier four is similar to the lockdown to what we saw in the virus back in march and april of last year, all essential businesses are closed, people encouraged to stay home, to only leave home for emergencies when they have to travel for work. we are hearing that schools are delaying opening across england after the christmas holiday. that is secondary schools here

has approved the astrazeneca-oxford vaccine. how big an impact would such a vaccine in the united states have? you talk about the super low temperatures, the pfizer vaccine biggeste held that, how -- how big a problem is that cold chain? chain storage is a challenge. process that is not something we normally use, so the infrastructure was not already there prior to distributing this vaccine. there are places that have the infrastructure, but they are -- or are relatively few. fewerderna vaccine has cold chain storage issues. what we are hearing is places that have had challenges with orting the ultralow freezers being able to distribute the large number of doses are going with moderna and pfizer vaccines are being allocated to places that can manage the process easier. the astrazeneca vaccine and some of the other ones that are further in the pipeline that should not as far in the pipeline have fewer cold chain storage issues. that will be huge globally where cold chain can be a real challenge. theaw the reduction in challenges

astrazeneca is seeing the oxford vaccine is 73% effective, 80% after the second. pfizer—biontech and moderna over 95%, so should people be worried about this? there will not get a choice, none of us will get a choice about which vaccine we have? we also want to remember that those are in trials and sometimes efficacy can be lower in real life situations, so i think between the two choices right now, really, in regular use, will be more similar, so i not be concerned about small differences between the different types of vaccines right now. what would you say to people who are nervous about vaccines anyway, who are seeing things by many of us have no idea of what we're seeing as misinformation or truth? look up reputable sources, people you trust. i see a lot of my friends who are healthcare professionals who are sessions, scientist and the front lines were getting vaccinated themselves, so i think when you have that kind of confidence among people who are most closely involved with this type of science in these type of trials and to have seen covid on the front

more on the oxford astrazeneca vaccine after her past date. time now to get the news, travel and weather where you are. good morning from bbc london, i'm alpa patel. london's nightingale hospital remains on standby for use, nhs england has insisted, despite the removal of some equipment from the site. nhs england sent a letter to trusts a week ago, asking them to plan for the use of additional facilities, such as the nightingale hospitals, amid rising numbers of patients with the virus. meanwhile ambulances have been seen queueing outside hospitals in london due to a reported shortage of beds. a major incident has been declared in essex because of the increased pressure that covid—19 is putting on health services. the number of patients receiving treatment has increased to levels higher than those seen in the peak of the first wave in spring. declaring the major incident enables the county to seek further support from the government to address the pressures. fulham's premier league match at tottenham is in doubt tonight. because of new coron

astrazeneca is seeing the oxford vaccine is 73% effective, 80% after the second. isa biontech over 95%, so second. isa biontech over 95%, so should people be worried about this? there will not get about this? there will not get a choice, none of us will get a choice about which vaccine we have? we also want to remember that those are in trials and sometimes efficacy can be lower in real life situations, so i think between the two choices right now, really, in regular use, will be more similar, so i not be concerned about small differences between the different types of vaccines right now. what would you say to people who are nervous about vaccines anyway, who are seeing things by many of us have no idea of what we're seeing as misinformation or truth? look up misinformation or truth? look up reputable sources, people you trust. i see a lot of my friends who are healthcare professionals who are sessions, scientist and the front lines we re scientist and the front lines were getting vaccinated themselves, so i think when you have that kind of confidence among people

today at six: the oxford/astrazeneca vaccine is approved for use in the uk. another tool in the fight against covid — 100 million doses are on order — it will be rolled out from next week. we have two valid vaccines and we are racing to get them out. on the downside, there is a new strain of the virus which is spreading much faster and surging across the country. it comes as the number of deaths reported in last 2a hours jumps to 981. also tonight: with covid infections surging millions more in england head into tier 4 from midnight — three quarters of the population now face the toughest rules. and now schools are affected — the majority of secondary pupils in england will not return to their classrooms till mid january. as mps vote overwhelmingly for borisjohnson‘s brexit trade deal, the prime minister says britain will have its cake and eat it. good evening and welcome to the bbc news at six. the uk medicines regulator has approved the oxford astrazeneca coronavirus vaccine. along with the pfizer vaccine that's already been given the green light,

the coronavirus vaccine developed by astrazeneca and oxford university becomes the second vaccine in the uk to receive regulatory approval. britain's health secretary says the first jobs will be in the new year. today's news is great news for the ability of the vaccine to make us safe, and make us say faster than we previously could have done. the uk regulator has proved that two standard doses should be given at an interval of between four to 12 weeks to be most effective. the effectiveness was high, up to 80%, when there was a three month interval between first and doses, which is the reason for our recommendation. the news comes as more parts of england are expected to be moved into the highest level of coronavirus restrictions, tier 4. politicians in the uk are debating legislation, which would put the eu trade deal into uk law. the vote is expected in the next half an hour. hello and welcome if you are watching in the uk or around the world. the uk medicines regulator has approved the oxford—astrazeneca coronavirus vaccine, paving the way for millions more people to be immunis

approved a vaccine developed i oxford university and astrazeneca. the pharmaceutical giant pledged to make 1.3 billion doses available at cost to low and middle income countries. we have more from london. correspondent: if ever good news was needed in the u.k., it is now. numbers of new infections and hospitalizations are breaking records. daily deaths are almost as numerous as the daily peak in april, and clinics are sounding alarms that the health service is struggling to cope with the covid wave. a new announcement from the u.k. medicine regulator. >> the covid-19 vaccine from astrazeneca has been approved for people ages 18 and older with two standard doses, four to 12 weeks apart. correspondent: rollout begins january 4, with the oxford astrazeneca vaccine joining that have pfizer and biontech in use in the u.k. since december. both have advantages. at this london vaccination center, you can see the infrastructure needed to administer the pfizer biontech vaccine. you can hear the generators running, people need to be kept warm in the vaccine ne

the approval of the oxford astrazeneca vaccine, which is a fantastic achievement for british science. it's a great day, we are very proud. this is a really significant moment in the fight against this pandemic. it is, i think, a game—changing moment. this is the vaccine, more than any other, that will eventually bring coronavirus under control. unlike pfizer's, which needs ultralow temperatures, the oxford astrazeneca vaccine can be transported in a fridge, meaning every care home in the uk should now be in reach. the medicines regulator said no corners had been cut. with this approval of the second vaccine, we are another step closer in helping to defeat this virus. 0ur clear message is that you can have every confidence in the safety, in the effectiveness and in the quality of covid—19 vaccine astrazeneca. the vaccine uses a gene from the spike—shaped protein on the surface of coronavirus. this is put inside a modified, harmless virus. the vaccine instructs human cells to make the spike protein which prompts the immune system to create antibodies which can recognise and destro

the coronavirus vaccine developed by astrazeneca and oxford university becomes the second vaccine in the uk to receive regulatory approval. the study‘s director says it is a landmark moment. it's a moment to celebrate and to have some optimism about where we've got to today, and moving forward. but we have to keep up this battle against the virus. the government has ordered 100 million doses, enough to vaccinate 50 million people. the health secretary says the first jabs will be given in the new year. today's news is great news for the ability of the vaccine to make us safe. and make us safe faster than we previously could have done. the news comes as more parts of england are to expected be moved into the highest level of coronavirus restrictions, tier 4. eu leaders sign the post—brexit trade deal agreed with britain on the eve of its departure from the eu single market, it will now be flown to london. here, the prime minister is due to start a debate in the house of commons shortly — as he asks mps to back the brexit trade deal in a vote this afternoon we'll have special cove

but hopefully, we would get the astrazeneca oxford vaccine quite soofi. astrazeneca oxford vaccine quite soon. i am hopeful. can i ask about that, professor van—tam ? soon. i am hopeful. can i ask about that, professor van—tam?” soon. i am hopeful. can i ask about that, professor van-tam? ijust need to finish this point, i am very sorry. i'm going to finish. one can be held at 2—8 all the way through and it is much easier to split into smaller quantities and probably can go into people's homes.” smaller quantities and probably can go into people's homes. i wasjust going to ask on the oxford one, i was getting a little bit excited there because there is some discussion that might be given approval before christmas, can you give any indication about that one? lam give any indication about that one? i am hopeful, give any indication about that one? lam hopeful, again, that that give any indication about that one? i am hopeful, again, that that would happen. but it is entirely out of my hands. it is in the hands of the regulator, the mhra. they take

getting itself prepared to deliver the astrazeneca oxford vaccine which is the one that is easier to deliver in general practice. the reason the pfizer vaccine has been made available to general practices because of these pirated in our ability to access 80—year—olds. so we haven't sent out invitations yet. it will be happening probably next week. patient shouldn't just turn up and they shouldn't try to make appointments. they will be sent appointments. they will be sent appointments from general practice and it is really important that they understand these priority so that we don't end with people lower priority looking on idols trying to get the vaccine because that simply won't happen. i think there are some problems, i think there is evidence that people ignore letters, that's the thing, and of course there is already a reluctance for people to be the first receivers of this vaccine so have are gps tackling this? you say they have trust, people within the community trust by medical centres. that one to one to get people to come in, how are you advising gps and nurses in the

the approval of the oxford astrazeneca vaccine, which is a fantastic achievement for british science. it's a great day, we're very proud. this is a really significant moment in the fight against this pandemic. it is, i think, a game—changing moment. this is the vaccine, more than any other, that will eventually bring coronavirus under control. unlike pfizer's, which needs ultra low temperatures, the oxford astrazeneca vaccine can be transported in a fridge, meaning every care home in the uk should now be in reach. the medicines regulator said no corners had been cut. with this approval of the second vaccine, we are another step closer in helping to defeat this virus. our clear message is that you can have every confidence in the safety, in the effectiveness and in the quality of covid—19 vaccine astrazeneca. the vaccine uses a gene from the spike—shaped protein on the surface of coronavirus. this is put inside a modified, harmless virus. the vaccine instructs human cells to make the spike protein, which prompts the immune system to create antibodies which can recognise and destr

it is not the astrazeneca oxford one, and you can bet your bottom pound that if the brits had been first to get the vaccine, as the government was trying to get the union flag on the packaging and all that kind of thing, they would be a lot more hullabaloo thing, they would be a lot more hulla baloo about the thing, they would be a lot more hullabaloo about the origins of this vaccine, be that as it may, this is great. it is cumbersome to deliver, as olivia has pointed out, but, yes, if we show some very non—johnsonian competence in the coming weeks and do manage to vaccinate people, particularly health care workers, who i think should be the first in line, without them, things are incredibly difficult, then the next will be care homes and the very elderly and rolling it back, so it could well be that the first quarter next year will begin to see an easing of restrictions. that's still a long way off. 0k, just one less point on this, olivia. eight hours after being signed off by the nhra, they could start. it does seem as if they could start. it does seem as if they have got everything

but the big advantage of the astrazeneca oxford university vaccine isn't just that it's cheap and it is, and there's a deal been imposed by oxford university on astrazeneca that it has to be sold in perpetuity at cost price, which is really important, but also it's a much easier vaccine to store. it can be stored at regular refrigerator temperatures. it doesn't have to be stored at, you know, 70 degrees centigrade below, which is what the pfizer vaccine has to be stored at, which requires specialized facilities. so it's a game changer in the sense that it's going to be much more widely available and much more practical as a vaccination, not just here in britain but elsewhere around the world as well. isa. >> matthew chance for us in london. thanks so much, matthew. let's get more on this. dr. peter drobak is an infectious disease and global health expert at the university of oxford here in london. good morning to you. great to see you once again. before we talk about the vaccine we just heard matthew chance talk about that's been approved i want to get your take first on the sobering

and not only the astrazeneca/oxford vaccine, but the johnson & johnson vaccine. then we have the novavax vaccine. we're going to need those vaccines in order to vaccinate the u.s. population. i do not think the mrna technology alone will be sufficient to vaccinate the u.s. population. so that is good news. we haven't seen the data coming out of the astrazeneca/oxford trials of late, so hopefully it's robust enough. the fda will green-light it so we can start releasing that one through emergency use authorization as well. and then the j&j, we need these vaccines in order to vaccinate the u.s. population. so it is potentially good news, and that's really the important message, isn't it, that people should not have to lose their lives at this point. this is the time to hang on because vaccines are on the other side now, and no one has to lose their lives and could live a normal, healthy life once they're vaccinated. >> we need those vaccines and we need people to get vaccinated. dr. peter hotez, appreciate your time. thank you. >>> and a quick programming note, from

you're in oxford where one of those vaccine tests has began and that is astrazeneca oxford. start off by talking about what is the people's vaccine and what are the inequities right now? who will get this vaccine, what countries and what countries want? ofvaccine is a coalition organizations like amnesty, frtline aids, global justice, oxfam. its led by oxfam and unaids. comes so many people ngos,ic's, experts, patient groupsrom all over the world. the united for one aids, which has a peoe vaccine, not a prophet vaccine. so basically we are calling for vaccinion that is available for all people at risk and and for everybody once we have enough doses. but not the way it is happening now where if you happen to be born in a rich country, you can the vaccine. if you happen to be born in poor countries country, you don't. yesterday in the u.k., they started vaccinating older people and there was some clapping. it was a lot of joy. of course, it is brilliant, there is hope this problem tt we are all sfering from- there is a light at the end of the tunnel. however, that joy is only

you're in oxford where one of those vaccine tests has began and that is astrazeneca oxford. start off by talking about what is the people's vaccine and what are the inequities right now? who will get this vaccine, what countries and what countries want? ofvaccine is a coalition organizations like amnesty, frontline aids, global justice, oxfam. it is led by oxfam and unaids. comes so many people ngos,ic's, experts, patient oups from all over the world. thunited for one aids, which has a pple vaccine, not a prophet vaccine. so basically we are calling for vaccation that is available for all people at risk and and for everybody once we have enough doses. but not the way it is happening now where if you happen to be born in a rich country, you can the vaccine. if you happen to be born in poor countries country, you don't. yesterday in the u.k., they started vaccinating older people and there was some clapping. it was a lot of joy. of course, it is brilliant, theris hope this problemhat we arell suffeng from- there is a light at the end of the tunnel. however, that joy is only li

today the uk medicines regulator gave the go—ahead for the oxford astrazeneca vaccine — signalling a landmark moment in the fight against coronavirus. it comes as the uk announced a further 981 deaths in the past 2a hours — the highest figure since april. but as the news of the vaccine was received, it was also announced that roughly 20 million more people across england are set to join the toughest tier 4 covid restrictions. from midnight tonight, the midlands, north east, parts of the north west and parts of the south west are among those escalated to tier 4 — with people asked to stay at home and in another of today's announcements — it was confirmed that the reopening of secondary schools in england will be delayed untiljanuary 18th for most pupils. however most primary schools will go back as planned. meanwhile, in the republic of ireland, what's been described as "full scale" level five restrictions, will be reimposed untiljanuary 31st in a bid to contain the spread of covid—19. but first — on the approval of the oxford astrazeneca vaccine and what it means for the uk

the uk government has approved the astrazeneca oxford covid-19 vaccine. first doses are being released today so that vaccinations will begin early in the new year. it added that it aims to supply millions of doses in the first quarter as part of its deal with the uk government it supply up to 100 million doses in total. shares are up on the development. in other vaccine news, moderna says that it will offer its new covid-19 treatment to its own employees, contractors and board members according to the "wall street journal" oig, t, the com says it is aimed at providing an additional layer of protection to workers delivering the vaccine and that the program would be separate from the doses committed to the u.s. government and chinese vaccine developer sinopharm said interim results showed a 79% efficacy rate the result clears the minimum requirements for chinese regulators and the group has applied for market approval. >>> and hedge fund manager reportedly eyeing a move into venture capital, according to the financial "times," loeb's third point is raising

the astrazeneca—oxford vaccine is based on what we call a viral vector. the majority of the respons is after the first dose. actually, you get a relatively modest boost with the second dose. and that is why they can perhaps be used in different fashions. so, if you had yourfirstjab of the pfizer vaccine, you might be rather disappointed not to be getting it within that three—week time frame, the second jab, i mean. yeah, i am not sure actually the roll—out of single doses is really... the majority of that will be applied to the astrazeneca vaccine, rather than the pfizer vaccine, is my understanding. obviously, this is a response to the crisis that is in front of us, but it is really important, therefore, that these vaccinations are rolled out as quickly as possible and do you have any concerns about the ability of the production process to keep up with the demand? certainly, that is going to be the rate—limiting factor in terms of getting the vaccines out there. we hope it won't be too much of a delay, but it does represent one of the huge challeng

the i reports the oxford/astrazeneca jab will be rolled out from next week, with enough vaccines on order to cover all uk adults. the daily mirror says covid has claimed its highest daily death toll since april. the financial times also picks up on the latest coronavirus figures released today, saying the uk is in a "very dangerous situation" as it faces a "grim and depressing picture" of rising infections and deaths as millions more are placed in the tightest tier of restrictions. the guardian carries a picture of borisjohnson signing the uk's brexit trade deal with the eu inside 10 downing street amid criticism of limited time for scrutiny. the times says the deal marks an end to britain's a7—year close relationship with the eu as well as putting a full stop to decades of tory infighting over europe. the daily express lends its support to the brexit deal, saying britain is finally free from the eu. and it adds borisjohnson is confident a game—changing vaccine will end the uk's "covid nightmare". while the daily mail reflects on the oxford covid vaccine and a brexit trade deal both b

could soon approve the oxford astrazeneca vaccine. meanwhile, logistical issues are delaying the delivery of the pfizer biontech vaccine to countries in the european union. those hundreds of thousands of doses are now being dispatched. let's get more on both of those stories. our correspondents are covering all developments across europe. salma abdelaziz in london, cyril vanier in paris. we're seeing a tragic milestone for the u.k. as the country fights off this new variant. talk to us about the challenges the country is facing this time around, and how it compares to that peak we saw in april. >> reporter: by a lot of measures, this is worse than the first wave. we are looking at an unprecedented infection rate on monday, more than 41,300 new coronavirus cases recorded in this rcountry, breaking the daiy record since the pandemic began. there are more patients in hospital with coronavirus than ever before. the national health service says that they are teetering. they are struggling. they are on the edge. we heard from the london amb

all three of the lead candidates-- pfizer, moderna, astrazeneca-oxford university-- are amazing vaccines. each have their own merits. and all of them are 100% efficient in terms of blocking hospitalization and serious illness. so take whichever you can get first, and the sooner you will be protected. >> diaz: dr. david agus, thank you. despite the vaccine's arrival, the pandemic is getting worse. hospitalizations and deaths setting devastating new records. cbs' danya bacchus is in los angeles. >> reporter: americans are now feeling the pain of gathering over thanksgiving. hospitals nationwide, overwhelmed. hospitalizations this week up in 28 states, 19 of them setting records. tonight, there are no i.c.u. beds left in mississippi. the morgue is doubling capacity in fort worth, texas. new york city will end indoor dining beginning monday. restaurant owners are frustrated. >> this is not because you're getting sick in the restaurants. this is because we cannot control people to stay away from each other. >> reporter: covid triage tents are going up in california, the state reporting its hi

regulators have authorized use of the oxford astrazeneca vaccine. the statement said it went through rigorous clinical trials and met strict safety standards. the u.k. prime minister boris johnson tweeted it was fantastic news and a triumph for british science. brittain is using the pfizer biontech vaccine and that will continue as well. this news comes from the u.k. as experts in the united states warn america's vaccine rollout isn't moving quickly enough. i spoke earlier with cnn medical analyst about the concerns here in the united states. >> you are a public health professional. this is something i know shakes you to your core when you see that vaccines are not being rolled out here in the united states at the pace at which they need to be rolled out. and i've been really interested to hear from you because you're not trying to blame people or point fingers, you're saying, we need to see what's wrong and fix it. >> that's right. this is not about blame. this is about introspection and having the humility to say this is the most ambitious vaccine

government is expected to approve the astrazeneca oxford vaccine within days. alibaba shares sinking as chinese authorities tell ant group to shrink its business model. is the whole chinese tech sector now at risk? this is bloomberg surveillance. i am in for francine lacqua and tom keene, both of whom have a day off. let's check the headlines you need to know about. i

. >> overnight england authorized the vaccine made by astrazeneca and oxford university for use. vice president-elect harris and her husband received the moderna vaccine yesterday in a predominantly black washington, d.c. neighborhood as they seek to boost public trust. >> president-elect biden is slamming the trump administration over the pace of the vaccine rollout. a new battle raging over the race to vaccinate the nation. >> a few weeks ago, trump administration suggested that 20 million americans could be vaccinated by the end of december. with only a few days left in december, we've only vaccinated a few million so far. >> reporter: the trump administration is facing new criticisms over the number of vaccine doses doled out in december across the country, just over 2 million cases delivered so far, well under the goal of 20 million by the end of the year. the coronavirus task force says that may not happen until the end of january. >> we certainly are not at the numbers that we wanted to be at the end of december. >> reporter: admiral brett jiroir, the coordinator for the c

today at six: the oxford/astrazeneca vaccine is approved for use in the uk. another tool in the fight against covid — 100 million doses are on order — it will be rolled out from next week. we have two valid vaccines and we are racing to get them out. on the downside, there is a new strain of the virus which is spreading much faster and surging across the country. it comes as the number of deaths reported in last 24 hours jumps to 981. also tonight: with covid infections surging millions more in england head into tier 4 from midnight — three quarters of the population now face the toughest rules.

i also want to welcome the astrazeneca oxford vaccine that will help deliver our health in the future and all the great work that all our health workers are doing and our communities across the country fighting covid. i hope that all members opposite willjoin us in voting for the future relationship bill today to support our farmers, our fishermen, bill today to support our farmers, ourfishermen, our car bill today to support our farmers, our fishermen, our car industry and finally delivering on the referendum result. the public have consistently voted to leave the eu over the last four and voted to leave the eu over the last fourand a voted to leave the eu over the last four and a half years, including voted to leave the eu over the last fourand a half years, including in tiverton and honiton, but farmers in my constituency and across the whole of the united kingdom will be pleased to see that we are leaving with a deal. sheep farmers across the industry, across the whole united kingdom, who were facing ta riffs of united kingdom, who were facing tariffs of almost 50 cents... studio:

the ‘i' reports the oxford/astrazeneca jab will be rolled out from next week, with enough vaccines on order to cover all uk adults. the daily mirror says covid has claimed its highest daily death toll since april. the financial times also picks up on the latest coronavirus figures released today, saying the uk is in a "very dangerous situation" as it faces a "grim and depressing picture" of rising infections and deaths as millions more are placed in the tightest tier of restrictions. according to the independent, critically ill patients are being transferred from the south of england to hospitals hundred of miles away, as nhs bosses reveal london is set to run out of critical care beds within a week. the guardian carries a picture of borisjohnson signing the uk's brexit trade deal with the eu inside 10 downing street amid criticism of limited time for scrutiny. the daily express lends its support to the brexit deal, saying britain is finally free from the eu, and it adds borisjohnson is confident a game—changing vaccine will end the uk's "covid nightmare." while the daily mail refle

the data packages for the astrazeneca oxford vaccine have been arriving. we expect a further package in the coming days. the committees will be aware of the publication in the la ncet aware of the publication in the lancet just yesterday, a peer—reviewed journal, testifying to excellent and intensive work that has been done by the oxford group and astrazeneca. i would not be able to give the committee is a firm date, because the review is clearly a very active review. there will be questions and deliberations that we will be pursuing in exactly the same way as we have done for the pfizer—biontech vaccine. not to be able to give a firm date but we can assure the committees that work is proceeding intensively and with great scientific rigour. one of the features of the oxford astrazeneca data and trials is that there were two different doses that were part of the investigation. are you evaluating the use of both types, the full dose and the half dose, or just one of those? our regulatory review is all—encompassing. we will look at all available data th